(HRTX) Heron Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(HRTX) Heron Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Heron Therapeutics, Inc. 4P's Marketing Mix Analysis outlines the product offering, pricing, distribution channels, and promotional tactics and shows how they support market positioning and sales; the page includes a real preview/sample of the analysis so you can review style and content before buying—purchase the full version for the complete ready-to-use report.
Product
CINVANTI (IV aprepitant)
CINVANTI is Heron Therapeutics' prescription-only IV aprepitant, a 130 mg single-dose antiemetic used with highly or moderately emetogenic chemotherapy to prevent acute and delayed CINV. In 2025, Heron kept it focused on supportive-care oncology, where high-emetogenic regimens can trigger nausea in a majority of patients. The IV route fits clinic use when oral dosing is not practical.
SUSTOL (extended-release granisetron)
SUSTOL is a single-dose 10 mg subcutaneous extended-release granisetron used with moderately emetogenic chemotherapy, including anthracycline/cyclophosphamide regimens, to control both immediate and delayed CINV for up to 5 days.
Its one-injection design helps reduce repeat dosing, which can improve adherence and clinic workflow, while still delivering 5-HT3 receptor blockade across the full nausea and vomiting risk window.
For Heron Therapeutics, Inc., SUSTOL sits in the product mix as a specialist supportive-care therapy with a clear, procedure-linked use case and a differentiated long-acting profile.
ZYNRELEF (bupivacaine plus meloxicam)
ZYNRELEF (bupivacaine plus meloxicam) is Heron Therapeutics, Inc.'s fixed-dose, dual-acting non-opioid for postoperative pain, built for surgical pain management. One administration is designed to deliver analgesia for up to 72 hours, which can cut repeat dosing needs in the first 3 days after surgery. In 2025, that long-acting profile kept it tied to hospital and outpatient surgical use where duration matters most.
APONVIE (aprepitant injectable emulsion)
APONVIE is Heron Therapeutics, Inc.'s 30 mg intravenous aprepitant emulsion for preventing postoperative nausea and vomiting in adults. It moves Heron’s antiemetic portfolio beyond oncology and fits perioperative care, where PONV affects about 30% to 80% of surgical patients, and up to 80% in high-risk cases.
- IV, single-dose antiemetic
- Perioperative use
- Expands beyond oncology
- Targets high PONV risk
Biochronomer platform
Biochronomer is Heron Therapeutics, Inc.'s proprietary controlled-release platform, built to keep drug levels in the body for days to weeks after one dose. It supports the company's long-acting injectable strategy by reducing how often patients need repeat dosing. In 2025, this kind of delivery design matters because it can improve adherence and make acute-care products more practical.
- Controlled-release, single-dose platform
- Therapeutic levels for days to weeks
- Backs long-acting injectable plans
Heron’s Long-Acting Injectable Portfolio Targets Hospital Care
Heron Therapeutics, Inc.'s product mix is built on single-dose, long-acting care: CINVANTI and APONVIE for antiemesis, SUSTOL for up to 5 days of CINV control, and ZYNRELEF for up to 72 hours of post-op pain relief. The Biochronomer platform underpins these injectables and supports less repeat dosing. In 2025, this mix stayed centered on hospital and clinic use.
| Product | Use | Key duration |
|---|---|---|
| CINVANTI | CINV | Single dose |
| SUSTOL | CINV | Up to 5 days |
| ZYNRELEF | Post-op pain | Up to 72 hours |
| APONVIE | PONV | Single dose |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Heron Therapeutics, Inc. covering product, pricing, distribution, and promotion strategy.
Editable Excel File
Distills Heron Therapeutics’ 4Ps into a quick, decision-ready snapshot that eases analysis and speeds alignment.
Reference Sources
Provides a concise, traceable bibliography linking each Heron Therapeutics claim to primary industry reports, regulatory filings, and benchmark datasets for fast, defensible due diligence.
Place
U.S. hospital pharmacies
U.S. hospital pharmacies are a core place for Heron Therapeutics, Inc. because its antiemetics and postoperative pain drugs are physician-administered and tied to inpatient care. The U.S. has about 6,120 hospitals, and this channel gives fast access at the point of surgery and discharge. It fits products used when treatment starts inside the hospital, not on the retail shelf.
Ambulatory surgery centers
Ambulatory surgery centers are a strong fit for Heron Therapeutics, Inc. because ZYNRELEF and APONVIE match same-day workflows that need fast pain and nausea control. U.S. ASCs now handle about 60% of outpatient surgeries, and single-dose use cuts dosing steps and saves staff time. That matters in a market where efficiency drives case volume and margins.
Oncology clinics and infusion centers
Oncology clinics and infusion centers are the main site for CINVANTI and SUSTOL, since they are given where chemotherapy starts. In FY2025, this channel stayed important because antiemetic use is built into infusion protocols, so access depends on oncologist prescribing and clinic formulary approval. The setting helps prevent chemotherapy-related nausea and vomiting at the point of care.
Specialty distributor and wholesaler network
Heron Therapeutics, Inc. uses established U.S. specialty distributors to move hospital-based drugs, which helps clinics and hospitals keep shelves stocked and reorder fast. In the U.S., the "big three" wholesalers, McKesson, Cencora, and Cardinal Health, account for roughly 90% of drug distribution, so this channel supports broad national reach.
- Fast replenishment for care sites
- Broad U.S. availability
- Lower stockout risk
U.S.-focused commercial footprint
Heron Therapeutics, Inc. is headquartered in San Diego, California, and its marketed products are sold mainly in the U.S., so the place strategy is tightly tied to domestic demand and reimbursement. The model leans on institutional access, with field support aimed at hospitals and outpatient sites where prescribing decisions are made.
- San Diego HQ anchors U.S. control
- Sales are mainly domestic
- Focuses on institutional access
Heron’s Institutional Channel Powers U.S. Drug Access
Heron Therapeutics, Inc. sells mainly through U.S. hospitals, ambulatory surgery centers, and oncology clinics, so Place is institutional, not retail. In FY2025, this fit supported point-of-care use for ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, with the U.S. big three wholesalers handling about 90% of drug distribution. Headquarters in San Diego keeps sales and access focused on the domestic market.
| Channel | Why it matters |
|---|---|
| Hospitals and ASCs | Point-of-care use |
| Wholesalers | About 90% reach |
Full Version Awaits
Heron Therapeutics, Inc. Reference Sources
The preview shown here is the actual Heron Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with product, price, place, and promotion insights tailored to Heron’s portfolio and market positioning.
Promotion
Targeted sales force
Heron Therapeutics, Inc. uses a targeted sales force that calls on oncologists, anesthesiologists, surgeons, and hospital buyers, which fits physician-administered specialty drugs. The pitch is simple: better efficacy, longer duration, and less workflow friction. That matters in hospital care, where purchasing is often driven by committee review and formulary access, not broad consumer demand.
Medical affairs education
Heron Therapeutics, Inc. uses clinical data and scientific exchange to support adoption, especially with hospital decision-makers. Medical affairs education explains dosing, indications, and administration so clinicians can use the products correctly. That matters for formulary acceptance because hospitals want clear evidence, safe use, and fewer onboarding errors.
Conference and congress presence
Heron Therapeutics, Inc. uses oncology and perioperative congresses to meet clinicians where treatment choices are made, and that helps build prescriber and pharmacist awareness. Congress talks and booths also support product differentiation versus short-acting alternatives by showing fit, duration, and use-case data. This channel matters most in specialties with high meeting density and repeat prescribing.
Formulary and access support
Heron Therapeutics, Inc. uses promotion to support payer and hospital access, because specialty injectables often face prior authorization and formulary hurdles that slow use. In practice, access support is part of the commercial pitch: if a product is not placed well on hospital formularies or needs extra reimbursement steps, adoption drops fast.
- Focus: payer and hospital access
- Drives reimbursement support
- Helps formulary placement
- Reduces prior-authorization friction
Value-based product messaging
Heron Therapeutics, Inc. uses value-based messaging to stress single-dose convenience and up to 72-hour pain control with ZYNRELEF, which can reduce redosing and save staff time in busy hospitals and ambulatory surgery centers. That matters where throughput and recovery-room flow drive cost. In 2024, Heron reported $123.4 million in net revenue, showing why clear value proof matters.
- Single-dose use cuts redosing
- Prolonged effect supports workflow
- Best fit: hospitals and surgery centers
Heron’s Hospital-Focused Sales Engine Supports ZYNRELEF Growth
Heron Therapeutics, Inc. promotes its drugs with a focused field force, medical education, and congress activity aimed at hospital buyers and specialists. The message centers on clinical proof, easier use, and access support; that fits ZYNRELEF’s single-dose, up to 72-hour pain control in surgery settings. Heron Therapeutics, Inc. reported $123.4 million in net revenue in 2024.
| Promotion lever | Why it matters |
|---|---|
| Sales force | Targets hospital decision-makers |
| Medical affairs | Explains safe, correct use |
| Access support | Helps formulary placement |
Price
Premium specialty-drug pricing
Heron Therapeutics, Inc. uses premium specialty-drug pricing because its branded, prescription-only therapies are sold as physician-administered products, not retail drugs. That pricing fits a market where dosing, site of care, and clinical differentiation matter more than shelf price. The model supports higher per-unit value, which is typical for specialty pharma.
Single-administration value
Heron Therapeutics, Inc. prices around single-administration use because products like ZYNRELEF are built for one-dose or long-acting delivery, not repeated dosing. That lets the Company sell value on lower administration burden, fewer clinic touches, and less staff time versus multi-dose regimens. In surgery, one application can cover postoperative pain control for up to 24 hours, which supports premium pricing.
Institutional reimbursement
Heron Therapeutics, Inc.’s institutional reimbursement is driven by hospital outpatient and ambulatory surgery center payment rules, not retail cash price. In 2025, access still hinges on medical-benefit coverage, so payer contracts and facility agreements decide whether use is practical. That makes reimbursement approval the key price lever for adoption.
Formulary contracting
Formulary contracting can speed Heron Therapeutics, Inc. adoption in hospitals and group purchasing organizations, where more than 90% of U.S. hospitals buy through GPOs. Contracted pricing can win preferred status, which matters in institutional drugs with tight budget controls. Discounts and rebate terms are often the gatekeeper to formulary access, not just price.
- Preferred status can lift hospital access.
- GPO deals shape buying decisions.
- Discounts are standard in institutional pharma.
Patient support and co-pay help
Heron Therapeutics, Inc. can use patient support and co-pay help to cut out-of-pocket costs for eligible patients, which is common in specialty drugs. That matters because lower upfront cost can help patients start therapy sooner and stay on treatment longer.
Reduces patient cost burden
Supports treatment starts
Helps continuity of care
Heron’s ZYNRELEF Growth Hinges on Hospital Access, Not List Price
Heron Therapeutics, Inc. prices ZYNRELEF as a premium, hospital-billed specialty drug, so reimbursement and formulary access matter more than sticker price. In 2025, adoption still depends on medical-benefit coverage and GPO contracts, with more than 90% of U.S. hospitals buying through GPOs; co-pay help can also lower patient friction.
| Price lever | 2025 data | Impact |
|---|---|---|
| Hospital reimbursement | Medical benefit | Drives access |
| GPO contracting | 90%+ hospital reach | Shapes adoption |
| Patient support | Co-pay help | Cuts out-of-pocket cost |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.